O'Rourke Bridget 4

What Happened

• Bridget O'Rourke, a director of Penumbra, Inc. (PEN), was granted 589 restricted stock units (RSUs) on February 13, 2026. The award is reported as an acquisition at $0.00 per share (total reported acquisition value $0). This is a compensation award (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-13; reported on Form 4 filed 2026-02-18 (filed timely).
• Grant details: 589 RSUs, acquisition price $0.00 (award/grant).
• Shares owned after transaction: not specified in the provided filing data.
• Footnotes: a portion of the RSUs is subject to vesting; see vesting schedule below. No 10b5-1, tax‑withholding, or sale noted in this filing.

Context

• Vesting: The RSUs vest 1/4 on each of March 31, 2026; June 30, 2026; September 30, 2026; and December 31, 2026, subject to Ms. O'Rourke's continued service. If the specified merger closing (per the Jan 14, 2026 merger agreement with Boston Scientific) occurs before those dates, any unvested RSUs will fully vest on the closing, subject to continued service.
• What this means for investors: RSUs are a common form of director compensation; they do not represent immediately tradable shares until they vest. The economic value to the insider will depend on Penumbra's share price at vesting or upon any accelerated vesting event (e.g., the merger closing).